Afatinib, a second-generation irreversible EGFR tyrosine kinase inhibitor (TKI), targets EGFR mutation-positive NSCLC by broadly inhibiting receptors including EGFR, HER2, and HER4. Here, EGFR is linked to non-small cell lung carcinoma.